<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: P-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi>, the product of the MDR1 gene, is a transmembrane active efflux pump for a variety of environmental toxins and <z:chebi fb="0" ids="35703">xenobiotics</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Epidemiological studies have evaluated the association between MDR1 C3435T polymorphism and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> susceptibility </plain></SENT>
<SENT sid="2" pm="."><plain>However, published data are still inconclusive </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: To derive a more precise assessment of this relevance, we performed a meta-analysis, up to September 2010, of 5,196 cases with different <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types and 6,827 controls from 34 published case-control studies </plain></SENT>
<SENT sid="4" pm="."><plain>Summary odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for MDR1 C3435T polymorphism and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> were estimated using fixed- and random-effects models when appropriate </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The overall results suggested that the variant was associated with a moderately increased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk in <z:hpo ids='HP_0000001'>all</z:hpo> comparison models tested (OR = 1.26, 95% CI: 1.06-1.50 for TT vs. CC; OR = 1.19, 95% CI: 1.04-1.37 for CT vs. CC; OR = 1.15, 95% CI: 1.01-1.32 for recessive model; OR = 1.21, 95% CI: 1.06-1.38 for domain model, and OR = 1.14, 95% CI: 1.04-1.26 for allele contrast) </plain></SENT>
<SENT sid="6" pm="."><plain>In the subgroup analysis by <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> types, significant associations were found in <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (OR = 1.66, 95% CI: 1.24-2.21 for TT vs. CC; OR = 1.44, 95% CI: 1.14-1.82 for recessive model; OR = 1.41, 95% CI: 1.10-1.81 for domain model; and OR = 1.31, 95% CI: 1.13-1.52 for allele contrast) and <z:e sem="disease" ids="C0740457" disease_type="Neoplastic Process" abbrv="">renal cancer</z:e> (OR = 1.99, 95% CI: 1.37-2.90 for TT vs. CC; OR = 1.74, 95% CI: 1.25-2.42 for domain model; OR = 1.43, 95% CI: 1.09-1.88 for recessive model; and OR = 1.40, 95% CI: 1.17-1.68 for allele contrast) </plain></SENT>
<SENT sid="7" pm="."><plain>However, no significant associations were found in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, <z:hpo ids='HP_0012126'>gastric cancer</z:hpo>, and <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> for <z:hpo ids='HP_0000001'>all</z:hpo> genetic models </plain></SENT>
<SENT sid="8" pm="."><plain>In the ethnicity subgroup analysis, a significant association with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> among Caucasians was found under the dominant model, homozygote comparison, CT versus CC comparison, and allele comparison </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: In summary, this meta-analysis suggests that the MDR1 C3435T polymorphism is associated with <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> susceptibility, increasing the risk of breast and <z:e sem="disease" ids="C0740457" disease_type="Neoplastic Process" abbrv="">renal cancer</z:e> </plain></SENT>
</text></document>